Amprius Technologies, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 18, 2025, discloses significant changes to the executive leadership of Amprius Technologies, Inc. The report details the departure of the current Chief Executive Officer and the appointment of a successor, effective January 1, 2026.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and executive compensation arrangements.
Material Changes
- CEO Transition: Dr. Kang Sun will step down as Chief Executive Officer effective December 31, 2025. He will transition to the role of Executive Advisor and remain a member of the Board of Directors.
- New CEO Appointment: Mr. Tom Stepien, currently the Company's President, has been appointed Chief Executive Officer effective January 1, 2026.
- Compensation Adjustments:
- Dr. Sun's new role as Executive Advisor includes an annual salary of $633,000 with no eligibility for annual bonuses. He retains eligibility to vest in outstanding equity awards.
- Mr. Stepien's new role as CEO includes an annual base salary of $633,000 and eligibility for an annual cash bonus with a target of 100% of base salary.
- Mr. Stepien received a grant of 200,000 restricted stock units (RSUs) on December 19, 2025, vesting 25% after one year and the remainder quarterly over three years.
Outlook, Risks, and Management Commentary
Management stated that Dr. Sun's decision to step down is not the result of any disagreement regarding the Company's operations, policies, or practices. The filing notes that Mr. Stepien brings significant industry experience, having previously served as CEO of South 8 Technologies and co-founded Primus Power. No specific financial guidance or new risk factors were disclosed in this filing.
Key Facts for Investor Verification
- Confirm the effective date of the leadership transition (January 1, 2026).
- Review the full text of the amended employment agreement for Dr. Sun, which will be filed as an exhibit to the Form 10-K for the fiscal period ending December 31, 2025.
- Verify the vesting schedule and performance conditions for Mr. Stepien's 200,000 RSU grant.
- Monitor future filings for any financial impact related to the change in executive compensation structure.